Clene Prices $4M Registered Direct Offering at $3.28/Share
CLNN is trading near its 52-week low of $3.26 (5.2% below the low).
Summary
Clene priced a registered direct offering of 1.22 million shares at $3.28 per share, raising $4 million from existing shareholders including Chairman David Matlin, Kensington Capital Holdings, and the CEO. The price is a modest premium to the current $3.09 market price, reflecting insider support. Proceeds extend the cash runway to mid-Q1 2027, funding regulatory work on CNM-Au8 and manufacturing expansion. This follows the Q2 10-Q going concern warning and $21.5 million net loss; the raise is small relative to the burn but buys time ahead of the planned NDA submission in early Q4 2026. Watch for the NDA filing and any further financing needs.
At the time of this announcement, CLNN was trading at $3.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42.1M. The 52-week trading range was $3.26 to $13.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.